Prophylactic use of Tranexamic Acid during Caesarean Section in Preventing Postpartum haemorrhage– a Prospective Randomised Double Blind Placebo Controlled Study

Nargis, Nazlima; Dewan, Farhana

doi:10.3329/bjog.v33i2.43564

Cited by 8 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No alterations in vitals were observed in both the groups (p>0.05). Similar findings were noted by previous studies by Nargis et al 12 and Bhavana et al, 14 in which tranexamic acid was not associated with alteration of vitals during and after delivery.…”

Section: Discussionsupporting

confidence: 92%

“…Nargis et al documented that use of tranexamic acid was not associated with any side effects and or complications like thrombosis. 12 The observed difference in adverse effects between present study and reference study could be because the reference study only taken major adverse effect such as DVT etc. into account.…”

Section: Discussionmentioning

confidence: 61%

“…Our study findings were supported by findings of Nargis et al, in which significantly higher blood losses from both placental deliveries to the end of cesarean section and from end of CS to 2 hours postpartum in control group as compared to study group was observed (p<0.05). 12 Sentilhes et al also observed lower rate of clinically significant postpartum hemorrhage in tranexamic acid group as compared to placebo group (7.8% vs. 10.4%; P<0.05). 13 WOMAN trial also proved the efficacy of tranexamic acid in management of PPH.…”

Section: Discussionmentioning

confidence: 86%

“…Our study findings were supported by findings of Nargis et al, in which fall in hemoglobin was significantly higher in control group as compared to study group (p<0.05). 12 Similarly Bhavana et al observed greater fall in the hemoglobin and haematocrit in placebo group as compared to tranexamic acid group. 14 Vitals were stable throughout the observation period in females of both the groups before and after delivery in both the groups.…”

Section: Discussionmentioning

confidence: 92%

See 3 more Smart Citations

The effect of tranexamic acid on blood loss after vaginal delivery and caesarian section

Tiwari¹,

Kumari²,

Maurya³

2023

IJOGR

View full text Add to dashboard Cite

PPH is most common cause of maternal death, contributing to approximately 35% of maternal death all over the world. WHO (2017) recommended that tranexamic acid should be considered as a standard comprehensive PPH treatment package and must be used in all cases of PPH regardless of the cause of PPH.To evaluate the effectiveness and safety of intravenous Tranexamic acid (TA) for reduction of postpartum blood loss after vaginal delivery and LSCS and to record any adverse effects following its administration.This study was conducted as a randomized, double blind, placebo controlled trial on females at high risk of PPH and delivered vaginally or via LSCS at our Institute. All the participants were randomly categorized into two groups study group (tranexamic acid) and control group. The two groups were compared with respect to efficacy (amount of blood loss and incidence of PPH) and safety (vitals and side effects). Mean blood loss from the delivery of placenta to the end of delivery and from end of delivery to 2 hours postpartum was significantly lower in study group as compared to control group (p<0.05). Incidence of PPH was significantly higher in control group (p<0.05). There was no statistically difference in the vital at the time of delivery between two groups (p>0.05). Most common side effect due to tranexamic acid in study group was nausea (16%) followed by vomiting and diarrhea in 9% and 1% respectively. Tranexamic acid is an effective drug that can be used safely for prophylactic management of PPH regardless of its cause. This antifibrinolytic agent significantly reduce blood loss and incidence of PPH irrespective of type of delivery. Though, the drug is associated with minor side effects such as nausea, vomiting and diarrhea, it was not associated with major complications, thromboembolic phenomenon and maternal or perinatal morbidity and mortality.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 92%

See 2 more Smart Citations

The effect of tranexamic acid on blood loss after vaginal delivery and caesarian section

Tiwari¹,

Kumari²,

Maurya³

2023

IJOGR

View full text Add to dashboard Cite

show abstract

“…Out of the 20 studies examining TXA effectiveness, 14 (70%) were randomized controlled trials (RCTs) [ 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ] and the rest non-randomized trials [ 32 , 33 , 34 , 35 , 36 , 37 ].…”

Section: Resultsmentioning

confidence: 99%

Tranexamic Acid for Postpartum Hemorrhage Treatment in Low-Resource Settings: A Rapid Scoping Review

Tran

Bar-Zeev

Schulte-Hillen³

et al. 2022

IJERPH

View full text Add to dashboard Cite

Tranexamic acid (TXA) effectively reduces bleeding in women with postpartum hemorrhage (PPH) in hospital settings. To guide policies and practices, this rapid scoping review undertaken by two reviewers aimed to examine how TXA is utilized in lower-level maternity care settings in low-resource settings. Articles were searched in EMBASE, MEDLINE, Emcare, the Maternity and Infant Care Database, the Joanna Briggs Institute Evidence-Based Practice Database, and the Cochrane Library from January 2011 to September 2021. We included non-randomized and randomized research looking at the feasibility, acceptability, and health system implications in low- and lower-middle-income countries. Relevant information was retrieved using pre-tested forms. Findings were descriptively synthesized. Out of 129 identified citations, 23 records were eligible for inclusion, including 20 TXA effectiveness studies, two economic evaluations, and one mortality modeling. Except for the latter, all the studies were conducted in lower-middle-income countries and most occurred in tertiary referral hospitals. When compared to placebo or other medications, TXA was found effective in both treating and preventing PPH during vaginal and cesarean delivery. If made available in home and clinic settings, it can reduce PPH-related mortality. TXA could be cost-effective when used with non-surgical interventions to treat refractory PPH. Capacity building of service providers appears to need time-intensive training and supportive monitoring. No studies were exploring TXA acceptability from the standpoint of providers, as well as the implications for health governance and information systems. There is a scarcity of information on how to prepare the health system and services to incorporate TXA in lower-level maternity care facilities in low-resource settings. Implementation research is critically needed to assist practitioners and decision-makers in establishing a TXA-inclusive PPH treatment package to reduce PPH-related death and disability.

show abstract

Prophylactic tranexamic acid in Cesarean delivery: an updated meta-analysis with a trial sequential analysis

Provinciatto,

Barbalho,

da Câmara

et al. 2024

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

Prophylactic use of Tranexamic Acid during Caesarean Section in Preventing Postpartum haemorrhage– a Prospective Randomised Double Blind Placebo Controlled Study

Cited by 8 publications

References 14 publications

The effect of tranexamic acid on blood loss after vaginal delivery and caesarian section

The effect of tranexamic acid on blood loss after vaginal delivery and caesarian section

Tranexamic Acid for Postpartum Hemorrhage Treatment in Low-Resource Settings: A Rapid Scoping Review

Prophylactic tranexamic acid in Cesarean delivery: an updated meta-analysis with a trial sequential analysis

Contact Info

Product

Resources

About